Keathley Justine, Garneau Véronique, Marcil Valérie, Mutch David M, Robitaille Julie, Rudkowska Iwona, Sofian Gabriela, Desroches Sophie, Vohl Marie-Claude
Centre Nutrition, Santé et Société (NUTRISS), Institut sur la Nutrition et les Aliments Fonctionnels (INAF), Université Laval, Québec City, QC, Canada.
School of Nutrition, Université Laval, Québec City, QC, Canada.
Front Nutr. 2022 Feb 14;8:768474. doi: 10.3389/fnut.2021.768474. eCollection 2021.
A recent systematic review, which used the GRADE methodology, concluded that there is strong evidence for two gene-diet associations related to omega-3 and plasma triglyceride (TG) responses. Systematic reviews can be used to inform the development of clinical practice guidelines (CPGs).
To provide guidance for clinical practice related to genetic testing for evaluating responsiveness to dietary/supplemental omega-3s and their impact on plasma lipids/lipoproteins/apolipoproteins.
Using the results of the abovementioned systematic review, the first CPGs in nutrigenetics were developed using the established GRADE methodology and AGREE II approach.
Three clinical practice recommendations were developed. Most gene-diet associations identified in the literature lack adequate scientific and clinical validity to warrant consideration for implementing in a practice setting. However, two gene-diet associations with strong evidence (GRADE quality: moderate and high) can be considered for implementation into clinical practice in certain cases: male -E4 carriers (rs429358, rs7412) and TG changes in response to the omega-3 fatty acids eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA) as well as a 31-SNP nutrigenetic risk score and TG changes in response to EPA+DHA among adults with overweight/obesity. Ethical and regulatory implications must be considered when providing nutrigenetic tests given the well-established link between genetic variation and Alzheimer's Disease.
Most of the evidence in this area is not ready for implementation into clinical practice primarily due to low scientific validity (low quality of evidence). However, the first CPGs in nutrigenetics have been developed for two nutrigenetic associations with strong scientific validity, related to dietary/supplemental omega-3 and TG responses.
最近一项采用GRADE方法的系统评价得出结论,有强有力的证据支持两个与ω-3和血浆甘油三酯(TG)反应相关的基因-饮食关联。系统评价可用于为临床实践指南(CPG)的制定提供信息。
为与基因检测相关的临床实践提供指导,以评估对饮食/补充ω-3脂肪酸的反应及其对血浆脂质/脂蛋白/载脂蛋白的影响。
利用上述系统评价的结果,采用既定的GRADE方法和AGREE II方法制定了营养遗传学领域的首个CPG。
制定了三项临床实践建议。文献中确定的大多数基因-饮食关联缺乏足够的科学和临床有效性,不值得在实践环境中考虑实施。然而,在某些情况下,有强有力证据(GRADE质量:中等和高)的两个基因-饮食关联可考虑应用于临床实践:男性ε4携带者(rs429358,rs7412)以及超重/肥胖成年人中ω-3脂肪酸二十碳五烯酸(EPA)和/或二十二碳六烯酸(DHA)与TG变化的关系,还有一个31个单核苷酸多态性的营养遗传风险评分以及超重/肥胖成年人中EPA+DHA与TG变化的关系。鉴于基因变异与阿尔茨海默病之间已确立的联系,在提供营养基因检测时必须考虑伦理和监管问题。
该领域的大多数证据尚未准备好应用于临床实践,主要原因是科学有效性低(证据质量低)。然而,已针对与饮食/补充ω-3和TG反应相关的两个具有强有力科学有效性的营养遗传关联制定了营养遗传学领域的首个CPG。